Shalby Ltd.
Snapshot View

200.25 ▼0%

23 July 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.shalby.org
Financial Indicators
Market Cap 2,167.22 Cr.
Earnings per share (EPS) 3.93 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 51.12 Trailing Twelve Months Ending 2021-03
Industry PE 223.80 Trailing Twelve Months Ending 2021-03
Book Value / Share 77.28 Trailing Twelve Months Ending 2021-03
Price to Book Value 2.60 Calculated using Price: 200.65
Dividend Yield 0.50 Period Ending 2020-03
No. of Shares Subscribed 10.80 Cr. 108,009,770 Shares
FaceValue 10
Company Profile

The company was originally incorporated as Shalby Hospital Private Limited on August 30, 2004, at Ahmedabad, Gujarat, India, as a private limited company under the Companies Act, 1956. Subsequently, the company was converted to a public limited company, and a fresh certificate of incorporation consequent upon change of name on conversion to a public limited company was issued by the Registrar of Companies, Ahmedabad, Gujarat (RoC) on May 15, 2006, in the name of Shalby Hospital Public Limited. The name of the company was subsequently changed to Shalby Hospitals Limited, and a fresh certificate of incorporation, consequent upon change of name was issued by the RoC on July 26, 2006. Thereafter, the name of the company was changed to Shalby Limited, and a fresh certificate of incorporation, consequent upon change of name was issued by the RoC on February 13, 2008.

Headquartered in Ahmedabad, India, the company has a domestic and overseas outreach through a network of hospitals in India, and Outpatient Clinics and SACE located in India, Africa, and the Middle East. Having strong presence in western and central India and focus on Tier - I and Tier - II cities, its hospitals operate across five states, its Outpatient Clinics operate across 37 cities in 12 states in India, and its SACE are present in seven cities in six states in India. The company’s international footprint consist five Outpatient Clinics and one SACE in Africa, and two SACE in the UAE. It is expanding its footprint in western and central India with hospitals being set up in Nashik and Vadodara.

Business area of the company

The company is one of the leading multi-specialty chains of hospitals in India. Its hospitals are tertiary care hospitals, few of which also offer quaternary healthcare services to patients in various areas of specialisation such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, and renal transplantations.

Major events and milestones of the company

  • 2007: Established and commenced operations of its first multi-specialty hospital, SG Shalby, at Sarkhej Gandhinagar Highway in Ahmedabad.
  • 2013: Krishna Shalby commences operations.
  • 2013: Shalby Vapi commences operations.
  • 2015: Shalby Jabalpur commences operations.
  • 2016: Shalby Indore commences operations.
  • 2016: Executed a memorandum of understanding with ZH Private Limited to manage and operate Zynova Shalby.
  • 2016: Executed an O&M agreement with Kamesh Hospital to commence operations of Shalby Mohali.
  • 2017: Entered into an agreement with Bait Al Batterjee Medical Company LLC, Dubai, to provide outpatient orthopaedics and spine surgeries.

Awards and accreditations

  • 2010: Rajiv Gandhi National Quality Award.
  • 2011: FICCI Healthcare Operational Excellence Award.
  • 2012: Best Medium Enterprise Award.
  • 2013: Healthcare Service Provider Company of the Year Award (In the category for companies generating annual revenue below Rs 5,000 million).
  • 2014: Hercules Award.
  • 2014: The company of the Year Award (In recognition of valuable contribution towards healthcare).
  • 2014: Best Multi-specialty Hospital - Metro.
  • 2015: Emerging Tertiary Care Hospital of the Year Award.
  • 2016: Gujarat Ratna Award.
  • 2016: The Best Medical Tourism Centre of Gujarat Award.
  • 2017: The Best Hospital for Medical Tourism of Gujarat Award.
  • 2017: Best CSR Initiative in Healthcare Award.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
+1.99%
1 Month
+20.13%
3 Month
+75.66%
6 Month
+85.16%
1 Year
+178.90%
2 Year
+138.39%
5 Year
8 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 14.79 31.21 15.92 19.50 12.60 7.81 4.13 3.49
Return on Capital Employed (%) 17.84 38.23 21.84 13.34 12.21 9.15 6.94 7.49
Return on Assets (%) 9.88 20.47 8.64 8.49 4.61 4.42 3.12 2.72

Balance Sheet View Details

Particulars 8 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 102 141 168 205 251 751 780 799
Non Curr. Liab. 10 33 90 207 291 140 130 144
Curr. Liab. 36 40 90 92 199 138 88 83
Minority Int. 4 3 2 0 -1 0 0 0
Equity & Liab. 152 217 351 504 741 1,030 998 1,027
Non Curr. Assets 125 154 289 440 582 794 801 793
Curr. Assets 27 63 63 64 159 236 197 234
Misc. Exp. not W/O
Total Assets 152 217 351 504 741 1,030 998 1,027

Profit Loss View Details

Particulars 8 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 225 259 275 290 324 378 462 487
Other Income 5 3 2 2 7 10 9 17
Total Income 230 262 278 293 331 388 472 504
Total Expenditure -184 -196 -208 -235 -252 -299 -379 -404
PBIDT 46 66 70 58 78 89 93 100
Interest 0 -2 -5 -10 -11 -12 -9 -7
Depreciation -27 -11 -21 -11 -17 -23 -33 -36
Taxation -4 -14 -18 0 -22 -15 -19 -29
Exceptional Items
PAT 15 38 25 36 29 39 32 28

Cash Flow View Details

Particulars 8 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 95 5 123 5 60 14 43 55
Cash Fr. Inv. -9 -26 -62 -98 -153 -237 1 -31
Cash Fr. Finan. -86 24 -39 75 96 222 -51 -22
Net Change 0 3 22 -19 3 0 -6 3
Cash & Cash Eqvt 2 6 27 9 12 12 5 8

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 79.43 79.43 79.43 79.44 79.44 79.45 79.45 79.45 74.07
Public 20.57 20.57 20.57 20.56 20.56 20.55 20.55 20.55 25.93
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 23 Jul 2021
Updates
Shalby Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ( the SEBI LODR ) - Issuance of Corporate Guarantee'.
Tue, 13 Jul 2021
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Shalby Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 - Reg. 74(5) for quarter ended June 30, 2021
Mon, 12 Jul 2021
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Shalby Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 - Reg. 74(5) for quarter ended June 30, 2021

Technical Scans View Details

Fri, 23 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 0%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 0%
Cipla Ltd. 76,510.04 948.50 0%
Cadila Healthcare Ltd. 62,965.29 615.05 0%
Aurobindo Pharma Ltd. 56,484.48 964.00 0%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 0%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 0%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 0%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 0%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 0%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 0%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 0%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 0%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 0%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 0%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 0%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 0%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 0%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 0%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 0%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 0%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 0%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 0%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 0%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 0%